These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25405880)

  • 1. Re-evaluating the approach to drug target discovery in multidrug-resistant Gram-negative bacilli.
    Umland TC; Schultz LW; Russo TA
    Future Microbiol; 2014; 9(10):1113-6. PubMed ID: 25405880
    [No Abstract]   [Full Text] [Related]  

  • 2. [Development status of new antibacterials].
    Yamano Y
    Nihon Rinsho; 2012 Feb; 70(2):315-9. PubMed ID: 22413538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antibiotic development pipeline for multidrug‐resistant gram‐negative bacilli: current and future landscapes.
    Talbot GH
    Infect Control Hosp Epidemiol; 2010 Nov; 31 Suppl 1():S55-8. PubMed ID: 20929372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Creative targeting of the Gram-negative outer membrane in antibiotic discovery.
    MacNair CR; Tsai CN; Brown ED
    Ann N Y Acad Sci; 2020 Jan; 1459(1):69-85. PubMed ID: 31762048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE; Rybak MJ
    Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug-resistant gram-negative bacterial infections after liver transplantation - spectrum and risk factors.
    Zhong L; Men TY; Li H; Peng ZH; Gu Y; Ding X; Xing TH; Fan JW
    J Infect; 2012 Mar; 64(3):299-310. PubMed ID: 22198738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance.
    Sahm DF; Critchley IA; Kelly LJ; Karlowsky JA; Mayfield DC; Thornsberry C; Mauriz YR; Kahn J
    Antimicrob Agents Chemother; 2001 Jan; 45(1):267-74. PubMed ID: 11120976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predominance of Gram-negative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Taiwan, 1996-2003.
    Wu CJ; Lee HC; Lee NY; Shih HI; Ko NY; Wang LR; Ko WC
    J Microbiol Immunol Infect; 2006 Apr; 39(2):135-43. PubMed ID: 16604246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-adherence activity and antimicrobial durability of anti-infective-coated catheters against multidrug-resistant bacteria.
    Raad I; Reitzel R; Jiang Y; Chemaly RF; Dvorak T; Hachem R
    J Antimicrob Chemother; 2008 Oct; 62(4):746-50. PubMed ID: 18653489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of antibiotic resistance in the genomic era of multidrug-resistant Gram-negative bacilli, especially Enterobacteriaceae, Pseudomonas and Acinetobacter.
    Diene SM; Rolain JM
    Expert Rev Anti Infect Ther; 2013 Mar; 11(3):277-96. PubMed ID: 23458768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging issues in the management of infections caused by multi-drug-resistant, gram-negative bacilli.
    Rice LB
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-37-47. PubMed ID: 23577496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistant gram-negative infections.
    Fraimow H; Nahra R
    Crit Care Clin; 2013 Oct; 29(4):895-921. PubMed ID: 24094384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in multidrug-resistant gram-negative bacilli and the role of prolonged β-lactam infusion in the intensive care unit.
    Guervil DJ; Chau T
    Crit Care Nurs Q; 2013; 36(4):345-55. PubMed ID: 24002425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyethylene glycol-stabilized sulphur nanoparticles: an effective antimicrobial agent against multidrug-resistant bacteria.
    Choudhury SR; Roy S; Goswami A; Basu S
    J Antimicrob Chemother; 2012 May; 67(5):1134-7. PubMed ID: 22269475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A paradigm shift in drug development for treatment of rare multidrug-resistant gram-negative pathogens.
    Alemayehu D; Quinn J; Cook J; Kunkel M; Knirsch CA
    Clin Infect Dis; 2012 Aug; 55(4):562-7. PubMed ID: 22610933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes.
    Gudiol C; Tubau F; Calatayud L; Garcia-Vidal C; Cisnal M; Sánchez-Ortega I; Duarte R; Calvo M; Carratalà J
    J Antimicrob Chemother; 2011 Mar; 66(3):657-63. PubMed ID: 21193475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antimicrobial resistance of Gram-negative bacilli isolated from 13 teaching hospitals across China].
    Wang Q; Zhao CJ; Wang H; Yu YS; Zhu ZH; Chu YZ; Sun ZY; Hu ZD; Xu XL; Liao K; Xu YC; Zhang LY; Mei YN; Yang B; Ni YX
    Zhonghua Yi Xue Za Zhi; 2013 May; 93(18):1388-96. PubMed ID: 24025503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008.
    Kallen AJ; Hidron AI; Patel J; Srinivasan A
    Infect Control Hosp Epidemiol; 2010 May; 31(5):528-31. PubMed ID: 20334552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug-resistant bacteria isolated from patients hospitalised in Intensive Care Units.
    Wroblewska MM; Rudnicka J; Marchel H; Luczak M
    Int J Antimicrob Agents; 2006 Apr; 27(4):285-9. PubMed ID: 16545949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.